From the floor in Xianning: 14 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Archive — March 2026
Page 2 of 5 of this archive, newest first.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 17% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
A supplier suspends shipping to Saudi Arabia after 15 consecutive customs detentions
The route did not close because of a rule about peptides.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
Low endotoxin recovery: the interference nobody looks for
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
Spain health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
From the floor in Changsha: 23 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 16-day notice: how a compounding wind-down works in France
The document is four pages. Three of them are about dates.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What happens to a stopper after the fourth needle
Particulate matter is the oldest quality attribute in injectable manufacture and the one a private buyer is best placed to assess without instrumentation.
Lipohypertrophy, and the absorption it ruins
Repeated injection into the same small area produces lipohypertrophy — thickened, rubbery subcutaneous tissue with blunted and erratic absorption. It is common, it is…
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A design note on withdrawal trials, and why the run-in matters
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
From the floor in Hangzhou: 5 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What a 32% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The degradation product that elutes underneath the parent peak
Deamidation, oxidation, aggregation and hydrolysis account for nearly all of what happens to a peptide over time. Each has a characteristic residue, a characteristic…
Target dose, effective dose, and the distance between them
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite Halvard & Pike Apothecary of Portland, Maine over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a BCH mazdutide lot at 96.0%, against 93.7% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
REWIND was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Which results are findings and which are consequences of the weight loss
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 15% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
What actually helps, ranked by evidence
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
An interlaboratory comparison nobody had run
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Independent analysis puts a MKM liraglutide lot at 99.0%, against 97.4% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The United Kingdom declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
Aseptic technique for people who were never taught it
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…